6.08
-0.14(-2.25%)
Currency In USD
| Previous Close | 6.22 |
| Open | 6.21 |
| Day High | 6.28 |
| Day Low | 6.04 |
| 52-Week High | 23.4 |
| 52-Week Low | 4.92 |
| Volume | 657,388 |
| Average Volume | 2.31M |
| Market Cap | 277.96M |
| PE | -3.82 |
| EPS | -1.59 |
| Moving Average 50 Days | 7.23 |
| Moving Average 200 Days | 11.18 |
| Change | -0.14 |
If you invested $1000 in Capricor Therapeutics, Inc. (CAPR) 10 years ago, it would be worth $140.09 as of September 18, 2025 at a share price of $6.08. Whereas If you bought $1000 worth of Capricor Therapeutics, Inc. (CAPR) shares 5 years ago, it would be worth $1,093.53 as of September 18, 2025 at a share price of $6.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
GlobeNewswire Inc.
Sep 09, 2025 1:20 PM GMT
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today issued a statement regarding the U.S. Food and Drug A
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
GlobeNewswire Inc.
Aug 18, 2025 1:00 PM GMT
First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the National Institute of Allergy and Infectious Diseases (NIAID) SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeu
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
GlobeNewswire Inc.
Aug 08, 2025 12:30 PM GMT
– Second Quarter 2025 Financial Results and Corporate Update Rescheduled to Monday, August 11, 2025, at 4:30 p.m. ET –SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformati